This intranasal blend combines PT-141 and Oxytocin to support sexual arousal, emotional intimacy, and mood. By activating melanocortin and oxytocin pathways, it may naturally enhance connection, pleasure, and social engagement.
Benefits
May boost libido and sexual responsiveness
May enhance emotional bonding and intimacy
May improve mood, confidence, and social interaction
May support pleasure and connection through key brain pathways
Dosing
Dose: 100–400mcg (2-6 sprays)
2 sprays for a dose of 133mcg PT-141 and 66.6mcg of Oxytocin,
6 sprays for a dose of 400mcg PT-141 and 199.8mcg of Oxytocin.
Start with 2 sprays
Wait 15-20 minutes to assess nausea
Proceed with 2-4 more sprays for full effect
How to Use
Duration: As needed
Add L-theanine capsule 30 minutes prior to help with nausea
MOA
Melanocortin Receptor Activation:
PT-141 is a selective melanocortin receptor agonist that primarily targets melanocortin-3 (MC3R) and melanocortin-4 (MC4R) receptors located within the central nervous system. Activation of these receptors modulates neuroendocrine circuits involved in sexual desire and arousal.
Central Nervous System Pathways:
Unlike phosphodiesterase inhibitors that act via peripheral vasodilation, PT-141 operates centrally by influencing hypothalamic pathways responsible for sexual motivation and behavior. This mechanism directly enhances sexual drive independent of vascular function.
Dopaminergic and Oxytocinergic Modulation:
Stimulation of MC4R receptors enhances dopaminergic neurotransmission and promotes the release of oxytocin—both critical mediators of sexual arousal, bonding, and reward. This neurochemical modulation amplifies sexual desire and positive affective responses.
Autonomic and Neuroendocrine Regulation:
PT-141 influences sympathetic nervous system output and integrates neuroendocrine signals that coordinate arousal responses. These effects result in heightened sexual readiness and improved central activation of arousal networks.
Distinct Mechanistic Profile:
Through its central melanocortin-mediated mechanism, PT-141 provides a unique therapeutic pathway for addressing hypoactive sexual desire and arousal disorders. Its independence from nitric oxide–mediated vasodilation makes it effective in both male and female patients, including those unresponsive to PDE5 inhibitors.
More Information
Disclaimer: For Research Purposes Only – All products on this site are for Research and Development use only. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease. Celia Health is a supplier of research-use chemicals manufactured in a CGMP facility in the US. Celia Health is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act.
This product requires a prescription. After purchasing, you will receive instructions to schedule and complete your intake exam before your order can be fulfilled. Prescriptions are valid for one calendar year.